Published on 3 Aug 2023 on Zacks via Yahoo Finance
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 59.34%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.75 per share when it actually produced a loss of $1.02, delivering a surprise of -36%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.